European Journal of Neurology 2025 Sep;32(9):e70362. doi: 10.1111/ene.70362. Eva Sole-Cruz, Elise Van Obberghen-Blanc, Chloé Hirtz, Imene Bennour, Michel Lanteri-Minet, Anne Donnet Abstract Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but
